Eu· dae· mon
Combining “eu” (good) and ‘daimōn’ (spirit), Eudaemonia is a central concept in Aristotelian philosophy associated with positive virtue, excellence, and practical or ethical wisdom. Eudaemon Technologies is combining that essence with Industry 4.0 to revolutionise Sexual and Reproductive Health.
Eudaemon is a disruptive rapid platform product innovation engine with focus on Sexual and Reproductive Health (SRH). Formed in 2019, Eudaemon has a focus to provide superior SRH products options to every person for every situation. We are bridging internal and partner-based next-gen capabilities in Advanced Manufacturing, Material Science, and Human Centred Design to deliver benefits to consumers, manufacturers, brands, and health agencies. Currently we are focused on platform technologies across traditional and innovative Multipurpose Prevention Technologies (MPTs). Our unique approach to vertically integrate the global value chain is positioned to disrupt the nexus of platform interventions which make up portions of a new category we term the $150B Lifetech market (encompassing the $28B contraceptive market, $13B fertility market and $100B+ STD diagnosis and treatment markets). We are building products that change lives.
We develop unique equipment and processes for rapid prototyping of products through pre-clinical and initial clinical work. Currently we are integrating IOT, machine learning/AI, robotics, smart materials, and other Industry 4.0 concepts to disrupt legacy manufacturing and produce systems that are safer, cleaner, and more cost effective.
Medical Grade Materials Science
Eudaemon has exclusive access to FDA cleared materials and APIs, as well as innovative new formulations with opportunities in the SRH sector. Combined with extensive internal understanding, our capabilities in optimising both compounds (medicine) and delivery mechanisms (devices) allow us to produce materials for devices that offer enhancements in user desired features while increasing clinical benefits.
User Driven Design
We utilise co-design methodologies to inform design of our products and to pinpoint need by discussions with stakeholders. We are building on traditional methodology by bioneering new neuroscience and preference studies to improve on the way we actually understand how people interact with products. These methods have been designed to integrate with and clinical and regulatory processes to improve safety and effectiveness.
What if we could make a condom that people couldn’t wait to try? Producing a condom that people actually want to use would revolutionise safe sex, enhance family planning, sexual health strategies (reduce the 1 million new STIs contracted every day), save healthcare agencies millions worldwide, as well as disrupt a growing $8B market. Project Geldom is about making this concept a reality by creating better feeling condoms made from innovative materials called tough hydrogels. These tissue-like materials act like rubber, the “gold standard” for condom production used for over a century, but offer superior safe sex options with enhanced feel and self-lubrication, no adverse odours or tastes, and no allergic reactions.
EVE-M is a bold and innovative collaborative research project aiming to transform the sexual and reproductive health of women globally. EVE-M is one of the inaugural Medical Research Future Fund initiatives, and the only female-focused (and female led) project Women’s Sexual and Reproductive Health. EVE-M aims to provide major insights on how the microbiome can impact on sexual and reproductive health, and provide practical solutions to reduce the spread of sexually transmissible infections, bacterial vaginosis and HIV, and provide new innovation for contraception.
Eudaemon helps secure prestigious MRFF Funding
A bold and innovative collaborative research project into women’s sexual and reproductive health, led by Burnet Institute’s Professor Gilda Tachedjian, has won a major competitive funding grant to fast track its development from concept to outcome.
Eudaemon featured in Rolling Stone Better, Safer Sex: On the Hunt for a Condom People Will Actually Like
When biomedical engineer Robert Gorkin saw the Bill and Melinda Gates Foundation’s 2013 call for submissions for a next-generation condom, he was hardly a contraceptive innovator. Rather, his work focused on 3D-printing organs and prosthetics.
Next-generation condom secures $1 million government funding
A next-generation hydrogel condom developed with Swinburne research has secured a $1 million NSW Medical Devices Fund (MDF) grant that will help to fund manufacturing and human trials in late 2018.
Nick is an experienced management consultant with 20 years’ experience as an Executive Chairman, Managing Director, Consulting Partner, COO and HR Director working with large enterprises (including listed entities), government, private high growth ventures, not for profits and SMEs. Nick has extensive experience in helping executive teams manage complex and high risk matters and to originate and complete value adding deals (with expertise in strategic growth and transformation, operational excellence, workplace investigations, facilitation & mediation, IP commercialisation, corporate finance and M&A) and has raised $50+ million in corporate, venture, grant and philanthropic funding. Since 2018 Nick has chaired Eudaemon and has stewarded corporate growth.
Dr Robert Gorkin is a biomedical engineer and serial entrepreneur passionate about transforming innovative Industry 4.0 concepts to commercial reality focusing on social good. His experience includes working on five continents with world-class institutes and companies, varying from international corporations to startups and not-for-profits. He has been directly involved in disruptive startups leading to investment, products and sales, contributed to over 100 publications (3000+ citations), and secured $5M+ worth of international grants awarded in both academic and commercial positions. He has led Eudaemon related projects since conceptualizing the next generation condom in 2014.
Dr Simon Cook is a Fulbright Future Scholar, and Research Fellow at Swinburne University of Technology with a background in biotechnology, microbiology and entrepreneurship. After Simon was awarded his PhD in 2014 from the University of Wollongong in Molecular Microbiology and Bacterial Pathogenesis, Simon joined Eudaemon’s first project - Project Geldom building to a role as technology lead. Since 2016, Simon has managed hands-on engagement with partners and product development for Eudeamon projects. Simon recently completed a Fulbright at the Kinsey Institute in the US looking at pioneering biofeedback and neuroscience based consumer engagement.
Project Support by
Eudaemon Technologies Pty Limited
Level 32, 101 Miller Street
North Sydney NSW 2060
Level 32, 101 Miller Street
North Sydney NSW 2060